Library of Congress Cataloging-in-Publication Data

p. ; cm.
Includes bibliographical references.
ISBN 978-1-56772-117-1 (pbk.)

616.99'491—dc22
2008022331
AMERICAN ACADEMY OF OTOLARYNGOLOGY–HEAD AND NECK SURGERY

HEAD AND NECK SURGERY COMMITTEE

FACULTY

DEVRAJ BASU, MD PhD
ERIC T. BECKEN, MD
JOSEPH BRENNAN, MD
MARION E. COUCH, MD PHD
DANIEL G. DESCHLER, MD
DAVID W. EISELE, MD
CHRISTINE G. GOURIN, MD
PATRICK JOSEPH GULLANE, MD FRCS(C)
STEPHEN Y. LAI, MD PhD
WILLIAM P. MAGDYCZ, MD
KELLY MICHELE MALLOY, MD
JAMES P. MALONE MD
ABBY C. MEYER, MD
CHERIE ANN O. NATHAN MD
BRIAN NUSSENBAUM, MD
URJEET PATEL, MD
CECELIA E. SCHMALBACH, MD
THEODOROS N. TEKNOS, MD
MARILENE B. WANG, MD
WENDELL G. YARBROUGH, MD
BEVAN YUEH, MD MPH

With appreciation to all former committee members who contributed.
ACKNOWLEDGMENTS

The American Head and Neck Society Committee acknowledges the input from the Head and Neck Surgery and Oncology Committee and the Head and Neck Surgery Education Committee of the American Academy of Otolaryngology–Head and Neck Surgery, and the Council of the American Head and Neck Society. Appreciation is also extended to Douglas Denys, MD, for the illustrations and the AJCC for the use of staging information from the 6th edition of the AJCC Cancer Staging Manual.

This monograph has been endorsed by the American Head and Neck Society and The American Academy of Otolaryngology–Head and Neck Surgery.
I. Introduction .................................................................................. 8
   A. Upper Aerodigestive Tract Sites .............................................. 8
      1. Oral Cavity .......................................................................... 9
      2. Oropharynx ........................................................................ 9
      3. Hypopharynx ...................................................................... 10
      4. Larynx ............................................................................... 11
      5. Nasopharynx ...................................................................... 12
      6. Nasal Cavity and Paranasal Sinuses .................................... 13
   B. Radiation Therapy and Chemotherapy ................................. 14

II. American Joint Committee on Cancer (AJCC) Tumor Staging by Site .................................................. 16
   A. Oral Cavity ............................................................................ 16
   B. Oropharynx ........................................................................... 16
   C. Larynx .................................................................................. 17
   D. Hypopharynx ........................................................................ 19
   E. Nasal Cavity and Paranasal Sinuses ...................................... 20
   F. Salivary Glands ...................................................................... 21
   G. Neck Staging Under the TNM Staging System for Head and Neck Tumors (excluding nasopharynx and thyroid) ..... 22
   H. TNM Staging for the Larynx, Oropharynx, Hypopharynx, Oral Cavity, Salivary Glands, and Paranasal Sinuses ........ 23

III. AJCC Tumor Staging—Nasopharynx and Thyroid .......... 24
   A. Nasopharynx ......................................................................... 24
   B. Thyroid .................................................................................. 25

IV. Definition of Lymph Node Groups ......................................... 29

V. Conceptual Guidelines for Neck Dissection Classification .... 33
   A. Radical Neck Dissection ....................................................... 33
   B. Modified Radical Neck Dissection ....................................... 34
   C. Selective Neck Dissection .................................................... 35
   D. Extended Radical Neck Dissection ..................................... 37
I. INTRODUCTION

The tumor, node, metastasis (TNM) staging system allows clinicians to categorize tumors of the head and neck region in a specific manner to assist with the assessment of disease status, prognosis, and management. All available clinical information may be used in staging: physical exam, radiographic, intraoperative, and pathologic findings. Other than histopathologic analysis, biomarkers and molecular studies are not yet included in the staging of head and neck cancers.

Three categories comprise the system: T—the characteristics of the tumor at the primary site (this may be based on size, location, or both); N—the degree of regional lymph node involvement; and M—the absence or presence of distant metastases. The specific TNM status of each patient is then tabulated to give a numerical status of Stage I, II, III, or IV. Specific subdivisions may exist for each stage and may be denoted with an a, b, or c status. In general, early-stage disease is denoted as Stage I or II disease, and advanced-stage disease as Stage III or IV disease. Of importance is that any positive metastatic disease to the neck will classify the disease as advanced, except in select nasopharynx and thyroid cancers.

A. Upper Aerodigestive Tract Sites

The majority of tumors arising in the head and neck (other than non-melanoma skin cancers) arise from the squamous mucosa that lines the upper aerodigestive tract (UADT) and are predominately squamous cell carcinomas. The UADT begins where the skin meets the mucosa at the nasal vestibule and the vermilion borders of the lips and continues to the junction of the cricoid cartilage and the cervical trachea and at the level of the cricoid where the hypopharynx meets the cervical esophagus. The UADT is organized into several major sites that are subdivided to several anatomic subsites. The major sites include (1) the oral cavity, (2) the oropharynx, (3) the hypopharynx,
(4) the larynx, (5), the nasopharynx, (6) and the nose and paranasal sinuses.

1. Oral Cavity

The oral cavity is a common site for squamous cell cancers of the UADT, probably because it is the first entry point for many carcinogens. The anterior aspect of the oral cavity is the contact point of the skin with the vermilion of the lips extending posteriorly to the junction of the hard and soft palates, and with the anterior tonsillar pillars and the circumvallate papillae forming the posterior limits. The major subsites of the oral cavity are the lips, anterior tongue, floor of mouth, buccal mucosa, upper and lower alveolar ridges, hard palate, and retromolar trigone. The trigone consists of the mucosa overlying the anterior aspect of the ascending ramus of the mandible. Tumors of the oral cavity tend to spread regionally to lymph nodes of the submandibular region (Level I) and to the upper and middle jugular chain lymph nodes (Levels II and III).

Because of accessibility and the risk of involvement of bony structures, treatment with radiotherapy can lead to radionecrosis of the mandible or maxilla. Moreover, oral cavity squamous cell carcinomas may be less sensitive to chemotherapy and radiation, relative to oropharyngeal or laryngeal cancers. Thus, primary treatment for most tumors is surgical. Positive surgical margins, multiple involved lymph nodes, and/or extracapsular tumor extension call for consideration of postoperative chemoradiotherapy, to improve local disease control.

2. Oropharynx

This structure begins where the oral cavity ends at the junction of the hard and soft palates superiorly and the circumvallate papillae inferiorly and extends from the level of the soft palate superiorly, which separates it from the nasopharynx and to the level of the hyoid bone inferiorly, where the hypopharynx begins. The subsites of the
Oropharynx are the tonsil, base of tongue, soft palate, and pharyngeal walls. Cancers of the oropharynx often metastasize to upper and middle jugular chain lymph nodes (Levels II and III), but can also spread to retropharyngeal lymph nodes, which distinguishes them from oral cavity tumors and must be considered when treating oropharyngeal cancers. Tumors in this site are generally treated with radiotherapy, as a single modality for T1/2 or N0/1 stages. Increasingly, some of these cancers are associated with human papilloma virus 16 infection, especially in nonsmokers. However, for patients with more advanced disease, T3/4 or N2 b/c/3 staging, chemoradiotherapy most often with a concomitant approach has become standard. Cisplatin, administered during weeks 1, 4, and 7 has most often been studied and may be considered a standard. Nonetheless, other regimens, carboplatin, taxanes, and drug combinations, such as cisplatin or carboplatin with fluorouracil, are also reported. Induction chemotherapy before radiotherapy (or chemoradiotherapy) remains an investigational strategy.

3. Hypopharynx

The hypopharynx has its superior limit at the hyoid bone, where it is contiguous with the oropharynx and it extends inferiorly to the cricopharyngeus muscle, where it meets the cervical esophagus. The major subsites of the hypopharynx are the pyriform sinuses, the postcricoid region, and the pharyngeal walls. Tumors often present here at advanced stages and can be difficult to cure, and because of their location can impact swallowing and speech function adversely. Spread to the upper, middle, and lower jugular lymph nodes (Levels II–IV) and the retropharyngeal nodes is common in these cancers. Two other hallmarks of hypopharyngeal cancers are submucosal spread and skip areas of spread. Surgery had been the mainstay of primary treatment for hypopharyngeal cancers for many years, but increasingly radiotherapy and chemoradiotherapy are used to treat cancers in this location with success.
4. **Larynx**

The larynx is the most complex of the mucosal lined structures of the UADT. Its important roles in speech, swallowing, and airway protection make the treatment considerations of cancers of this structure varied and controversial. The larynx is bordered by the oropharynx superiorly, the trachea inferiorly, and the hypopharynx laterally and posteriorly. The larynx is comprised of a cartilaginous framework, and is subdivided vertically by the vocal cords into the supraglottic, glottic, and subglottic subsites. The supraglottic larynx includes the epiglottis, which has both lingual and laryngeal surfaces, the false vocal cords, the arytenoid cartilages, and the aryepiglottic folds. Anterior to the supraglottis is the pre-epiglottic space. This is a complex space with a rich lymphatic network that contributes to the early and bilateral spread of tumors that arise from supraglottic structures to upper, middle, and lower jugular chain lymph nodes.

The glottic larynx describes the true vocal cords, and where they come together anteriorly at the anterior commissure, as well as where they meet the mobile laryngeal cartilages at the posterior commissure. The glottic larynx extends from the ventricle to 1 cm below the level of the true cords. The vocal cords are lined with stratified squamous epithelia, which contrasts with the pseudostratified ciliated respiratory mucosa lining the remainder of the larynx. Glottic laryngeal cancers tend to metastasize unilaterally and spread regionally less commonly than supraglottic tumors do. Between the thyroid cartilage and the vocal cord lies the paraglottic space, which is continuous with the pre-epiglottic space. This serves as a pathway for submucosal spread of tumors from the glottis to the supraglottis, or vice versa, which is known as transglottic spread. The subglottic larynx starts 1 cm below the vocal folds and continues to the inferior aspect of the cricoid cartilage. While it is rare for tumors to arise initially in the subglottis, tumors arising in the supraglottic or glottic larynx commonly spread in a “transglottic” fashion to involve the
subglottic larynx. Subglottic tumors tend to metastasize to paratracheal (Level VI) as well as middle or lower jugular lymph (Levels III and IV) node groups.

Treatment of laryngeal cancers varies widely from center to center, and for early-stage lesions radiotherapy or transoral endoscopic excision are the most common treatment options. Both yield excellent tumor control, but proponents of each modality often disagree on the functional sequelae of the two types of treatment. However, good long-term functional data are lacking. Treatment of more advanced tumors can be even more controversial, but while total laryngectomy was long held as the gold standard for treating T3 and T4 larynx cancers, chemoradiotherapy has been shown to be quite effective in achieving local regional control, survival, and organ preservation. Concomitant chemoradiotherapy may be most appropriate for T3 primary lesions. Treatment of both sides of the neck must be taken into consideration when treating supra- and subglottic tumors, and unilateral neck treatment is considered for patients with advanced glottic tumors.

5. Nasopharynx

The nasopharynx is a cuboidal structure bounded anteriorly by the choanae at the back of the nose where pseudostratified ciliated columnar cells are found. The roof and posterior walls of the nasopharynx are made up of the sphenoid bone and the upper cervical vertebrae, covered with a stratified squamous epithelial lining. Inferiorly, at the level of the soft palate, the nasopharynx meets the superior oropharynx. The opening of the Eustachian tube is found at the posterior-superior aspect of either lateral nasopharyngeal wall; therefore, impingement of this opening by a nasopharyngeal tumor can lead to Eustachian dysfunction manifested by a middle-ear effusion and hearing loss. Thus, all adult patients with an unexplained unilateral middle-ear effusion, particularly in areas where nasopharyngeal carcinoma is endemic (such as southern China, northern
Africa, and Greenland), should have their nasopharynx examined. The adenoids, consisting of mucosa-covered lymphoid tissue, are found posteriorly and superiorly in the nasopharynx and are more prominent in children than adults.

While minor salivary tumors can occur in the nasopharynx, most nasopharyngeal cancers are derived from the mucosal lining and fit into one of the three histologic subtypes described by the World Health Organization (WHO). WHO Type I nasopharyngeal carcinoma (NPC) is keratinizing squamous carcinoma, and WHO Type II is nonkeratinizing squamous cell carcinoma. WHO Type III is an undifferentiated tumor, also known as lymphoepithelioma. The Epstein-Barr virus is thought to play a pathogenic role in the development of Type II and III tumors. Nasopharyngeal carcinoma may also metastasize to retropharyngeal and parapharyngeal lymph nodes, as well as lymph nodes along the upper, lower, and middle jugular (Levels II–IV) chains and the posterior triangle of the neck (Level V). Early-stage NPC is most often treated with radiotherapy alone, and in more advanced cases, T3/4 N+ concomitant chemotherapy is being increasingly utilized. Surgery is rarely used in salvage situations at the primary site or neck.

6. Nasal Cavity and Paranasal Sinuses

The paranasal sinuses consist of the paired maxillary sinuses, the superior frontal sinuses, the bilateral ethmoid system, and the central sphenoids. This region includes the lining of the nasal cavity (medial maxillary walls) as well as the nasal septum. The majority of sinonasal carcinomas arise in the maxillary sinuses and are most commonly squamous cell carcinomas, although adenocarcinomas are described, especially in woodworkers. Because of inherent bone involvement, initial treatment is usually surgical, with consideration for adjuvant radiation therapy based upon stage and pathologic findings. Reconstruction and rehabilitation, especially in cases with orbital involvement, may be prosthetic or tissue based. Sinonasal
carcinomas of the anterior skull base include a variety of pathologies. Standard treatment is multidisciplinary, including craniofacial surgical intervention with adjuvant radiation and chemotherapy.

B. Radiation Therapy and Chemotherapy

External beam radiation therapy (RT) alone or in conjunction with chemotherapy has a well-established role in the treatment of head and neck cancer as definitive therapy or as adjuvant to primary surgical treatment. The last two decades have seen tremendous technological developments in targeting and delivery of RT in a complex treatment site such as the head and neck. Three-dimensional (3-D) conformal RT marked a significant improvement over the conventional two-dimensional 3-field setup in better delineation of tumor volume and nodal volume. This improvement allows limited dosing to normal tissue, while adequately treating the tumor. However, 3-D conformal planning does not always result in optimal shielding of critical normal tissues (e.g., salivary glands and visual apparatus), due to current beam constraints.

Intensity-modulated radiation therapy (IMRT) allows for better sparing of such critical normal tissues by modulating the radiation beam in multiple small beamlets, while at the same time adequately covering the tumor volume. With the advent of IMRT, it is also very important for the clinician to be acutely aware of radiologic anatomy (levels of nodal disease, pathways of loco-regional spread of tumor, and delineation of postoperative tumor bed), while utilizing computed tomography, scan magnetic resonance imaging, and positron emission tomography scan for treatment planning.

Preoperative clinical and radiologic evaluation of disease is extremely important for postoperative radiotherapy planning, as tissue planes may be obscured after surgery. Such evaluation is also valuable in determining whether ipsilateral or bilateral neck disease needs to be addressed based on tumor location, extent, and size; ini-
tial nodal presentation; and likelihood of contralateral nodal involve-
mant. Certain primary tumor sites have a high risk of retropharyngeal
odal involvement (nasopharynx, piriform sinus, and tongue base),
and these nodal groups should be covered in RT target volumes for
these tumors. Approximately 20% of anterior tongue and floor of
mouth cancers may have skip nodal metastasis to Level IV nodal re-

Important considerations in RT planning following surgical resection
include a thorough evaluation of the surgical pathology report with
respect to resection margins, extension to soft tissue/bone, and per-
neural or lympho-vascular invasion at the primary site and size;
extra-capsular extension (ECE); and the number and level of nodal
involvement. Postoperative patients with ECE are at high risk for
loco-regional recurrence. Careful adjuvant treatment planning in-
cludes consideration of radiation dose (60–66 Gy), addition of con-
current chemotherapy (RTOG 95-01), extension of the RT clinical
target volume to include overlying skin, and elective irradiation of
contralateral neck nodes. The clinical target volume in radiation ther-
apy of a clinically or pathologically involved neck typically extends
up to the skull base to treat the highest neck nodes. In the contralat-
eral elective neck irradiation, the highest treated nodes are jugulo-
digastric nodes.

Adjuvant RT should ideally begin within 4–6 weeks following pri-
mary surgical resection and neck dissection, unless postoperative
complications significantly delay wound healing. Delaying adjuvant
therapy has been shown to significantly decrease loco-regional con-
trol.
II. AMERICAN JOINT COMMITTEE ON CANCER (AJCC)
TUMOR STAGING BY SITE

A. Oral Cavity

*Definition*: The anterior border is the junction of the skin and vermillion border of the lip. The posterior border is formed by the junction of the hard and soft palates superiorly, the circumvallate papillae inferiorly, and the anterior tonsillar pillars laterally. The various sites within the oral cavity include the lip, gingival, hard palate, buccal mucosa, floor of mouth, anterior 2/3 of tongue, and retromolar trigone.

<table>
<thead>
<tr>
<th>Stage</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>TX</td>
<td>Primary tumor cannot be assessed.</td>
</tr>
<tr>
<td>T0</td>
<td>There is no evidence of primary tumor.</td>
</tr>
<tr>
<td>Tis</td>
<td>Carcinoma is <em>in situ</em>.</td>
</tr>
<tr>
<td>T1</td>
<td>Tumor is 2 cm or less in greatest dimension.</td>
</tr>
<tr>
<td>T2</td>
<td>Tumor is more than 2 cm but not greater than 4 cm in greatest dimension.</td>
</tr>
<tr>
<td>T3</td>
<td>Tumor is more than 4 cm in greatest dimension.</td>
</tr>
<tr>
<td>T4 (lip)</td>
<td>Tumor invades through cortical bone, inferior alveolar nerve, floor of mouth, or skin of face—i.e., chin or nose.</td>
</tr>
<tr>
<td>T4a (oral cavity)</td>
<td>Tumor invades adjacent structures (e.g., through cortical bone, into deep [extrinsic] muscle of tongue [genioglossus, hypoglossus, palatoglossus, and styloglossus], maxillary sinus, skin of face).</td>
</tr>
<tr>
<td>T4b</td>
<td>Tumor invades masticator space, pterygoid plates, or skull base and/or encases the internal carotid artery.</td>
</tr>
</tbody>
</table>

*Note*: Superficial erosion alone of bone/tooth socket by gingival primary is not sufficient to classify as T4.

B. Oropharynx

*Definition*: The oropharynx includes the base of the tongue, the inferior surface of the soft palate and uvula, the anterior and posterior
tonsillar pillars, the glossotonsillar sulci, the pharyngeal tonsils, and the lateral and posterior pharyngeal walls.

T1  Tumor is 2 cm or less in greatest dimension.
T2  Tumor is more than 2 cm but not more than 4 cm in greatest dimension.
T3  Tumor is more than 4 cm in greatest dimension.
T4a Tumor invades the larynx, deep/extrinsic muscle of the tongue, medial pterygoid, hard palate, or mandible.
T4b Tumor invades the lateral pterygoid muscle, pterygoid plates, lateral nasopharynx, or skull base or encases the carotid artery.

C. Larynx

Site    Subsite

Supraglottis  Suprahyoid epiglottis
            Infrahyoid epiglottis
            Aryepiglottic folds (laryngeal aspect)
            Arytenoids
            Ventricular bands (false cords)
Glottis      True vocal cords, including anterior and posterior commissures, including the region 1 cm below the plane of the true vocal folds
Subglottis   Region extending from 1 cm below the true vocal folds to the cervical trachea

Primary Tumor (T)

TX  Primary tumor cannot be assessed.
T0  There is no evidence of primary tumor.
Tis  Carcinoma is in situ.
**Supraglottis**

T1  Tumor is limited to one subsite of the supraglottis, with normal vocal cord mobility.

T2  Tumor invades mucosa of more than one adjacent subsite of the supraglottis or glottis or region outside the supraglottis (e.g., mucosa of base of tongue, vallecula, medial wall of pyriform sinus), without fixation of the larynx.

T3  Tumor is limited to the larynx with vocal cord fixation and/or invades any of the following: postcricoid area, pre-epiglottic tissues, paraglottic space, and/or minor thyroid cartilage erosion (e.g., inner cortex).

T4a Tumor invades through the thyroid cartilage and/or invades tissues beyond the larynx (e.g., trachea, soft tissues of neck, including deep extrinsic muscle of the tongue, strap muscles, thyroid, or esophagus).

T4b Tumor invades prevertebral space, encases the carotid artery, or invades mediastinal structures.

**Glottis**

T1  Tumor is limited to the vocal cords(s) (may involve anterior or posterior commissure), with normal mobility.

T1a Tumor is limited to one vocal cord.

T1b Tumor involves both vocal cords.

T2  Tumor extends to the supraglottis and/or subglottis, and/or with impaired vocal cord mobility.

T3  Tumor is limited to the larynx with vocal cord fixation and/or invades paraglottic space, and or minor thyroid cartilage erosion (e.g., inner cortex).

T4a Tumor invades through the thyroid cartilage and/or invades tissues beyond the larynx (e.g., trachea, soft tissues of the neck, including deep extrinsic muscle of the tongue, strap muscles, thyroid, or esophagus).
T4b  Tumor invades prevertebral space, encases the carotid artery, or invades mediastinal structures.

Subglottis
T1  Tumor is limited to the subglottis.
T2  Tumor extends to the vocal cord(s), with normal or impaired mobility.
T3  Tumor is limited to the larynx, with vocal cord fixation.
T4a  Tumor invades cricoid or thyroid cartilage and/or invades tissues beyond the larynx (e.g., trachea, soft tissues of neck, including deep extrinsic muscles of the tongue, strap muscles, thyroid, or esophagus).
T4b  Tumor invades prevertebral space, encases the carotid artery, or invades mediastinal structures.

D. Hypopharynx

Definition: The hypopharynx includes the pyriform sinuses, the lateral and posterior hypopharyngeal walls, and the postcricoid region.

T1  Tumor is limited to one subsite of the hypopharynx and 2 cm or less in greatest dimension.
T2  Tumor invades more than one subsite of the hypopharynx or an adjacent site, or measures more than 2 cm but not more than 4 cm in greatest dimension without fixation of the hemilarynx.
T3  Tumor is more than 4 cm in greatest dimension or with fixation of the hemilarynx.
T4a  Tumor invades thyroid/cricoid cartilage, hyoid bone, thyroid gland, esophagus, or central compartment soft tissue.
T4b  Tumor invades prevertebral fascia, encases the carotid artery, or involves mediastinal structures.
**E. Nasal Cavity and Paranasal Sinuses**

*Definition:* The paranasal sinuses include the ethmoid, maxillary, sphenoid, and frontal sinuses.

**TX** Primary tumor cannot be assessed.

**T0** There is no evidence of primary tumor.

**Tis** Carcinoma is *in situ*.

**Maxillary Sinus**

*Definition:* The maxillary sinus is a pyramid-shaped cavity within the maxillary bone. The medial border is the lateral nasal wall. Superiorly, the sinus abuts the orbital floor and contains the infraorbital canal. The posterolateral wall is anterior to the infratemporal fossa and pterygopalatine fossa. The anterior wall is posterior to the facial skin and soft tissue. The floor of the maxillary antrum extends below the nasal cavity floor and is in close proximity to the hard palate and maxillary tooth roots.

**T1** Tumor is limited to the maxillary sinus mucosa, with no erosion or destruction of bone.

**T2** Tumor is causing bone erosion or destruction, including extension into the hard palate and/or middle nasal meatus, except extension to the posterior wall of the maxillary sinus and pterygoid plates.

**T3** Tumor invades any of the following: bone of the posterior wall of the maxillary sinus, subcutaneous tissues, floor, or medial wall of the orbit, pterygoid fossa, or ethmoid sinuses.

**T4a** Tumor invades anterior orbital contents, skin of cheek, pterygoid plates, infratemporal fossa, cribiform plate, sphenoid or frontal sinuses.

**T4b** Tumor invades any of the following: orbital apex, dura, brain, middle cranial fossa, cranial nerves other than maxillary division of trigeminal nerve (V2), nasopharynx, or clivus.
**Nasal Cavity and Ethmoid Sinus**

*Definition:* The nasal cavity includes the nasal antrum and the olfactory region. The subsites within the nasal cavity include the septum; superior, middle, and inferior turbinates; and olfactory region of the cribriform plate. The ethmoid sinus is made up of several thin-walled air cells. Laterally, the ethmoid sinus is bound by a thin bone called the lamina papyracea, which separates it from the medial orbit. The posterior border of the ethmoid sinus is close to the optic canal. The anterosuperior border or roof of the ethmoid is formed by the fovea ethmoidalis, which separates it from the anterior cranial fossa. The perpendicular plate of the ethmoid bone separates the ethmoid cavity into left and right sides.

T1 Tumor is confined to the ethmoid sinus with or without bone erosion.

T2 Tumor invades two subsites in a single region or extends to involve an adjacent region within the nasoethmoidal complex, with or without bony invasion.

T3 Tumor extends to invade the medial wall or floor of the orbit, maxillary sinus, palate, or cribriform plate.

T4a Tumor invades any of the following: anterior orbital contents, skin of nose or cheek, minimal extension to anterior cranial fossa, pterygoid plates, sphenoid or frontal sinuses.

T4b Tumor invades any of the following: orbital apex, dura, brain, middle cranial fossa, cranial nerves other than (V2), nasopharynx, or clivus.

**F. Salivary Glands**

*Definition:* The salivary glands include the parotid, submandibular, sublingual, and minor salivary glands.

T1 Tumor is 2 cm or less without extraparenchymal extension.

T2 Tumor is greater than 2 cm but not more than 4 cm without extraparenchymal extension.
T3 Tumor is more than 4 cm and/or extraparenchymal extension.
T4a Tumor invades the skin, mandible, ear canal, and/or facial nerve.
T4b Tumor invades the skull base and/or pterygoid plates and/or encases the carotid artery.

**G. Neck Staging Under the TNM Staging System for Head and Neck Tumors** (excluding nasopharynx and thyroid)

NX Regional lymph nodes cannot be assessed.
N0 There is no regional nodes metastasis.
N1 Metastasis is in a single ipsilateral lymph node, 3 cm or less in greatest dimension.
N2 Metastasis is in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension; or metastasis is in multiple ipsilateral lymph nodes, none more that 6 cm in greatest dimension; or metastasis is in bilateral or contralateral lymph nodes, none greater than 6 cm in greatest dimension.
N2a Metastasis is in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension.
N2b Metastasis is in multiple ipsilateral lymph nodes, none more that 6 cm in greatest dimension.
N2c Metastasis is in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension.
N3 Metastasis is in a lymph node more than 6 cm in greatest dimension.
U, L A designation of “U” or “L” may be given in addition to indicate the level of metastasis above the lower border of the cricoid cartilage (U) or below the lower border of the cricoid cartilage (L).
**Distant Metastasis (M)**

MX  Distant metastasis cannot be assessed.
M0  There is no distant metastasis.
M1  There is distant metastasis.

**H. TNM Staging for the Larynx, Oropharynx, Hypopharynx, Oral Cavity, Salivary Glands, and Paranasal Sinuses**

**Stage Grouping**

Stage 0  Tis  N0  M0
Stage I  T1  N0  M0
Stage II  T2  N0  M0
Stage III  T3  N0  M0  
                T1  N1  M0
                T2  N1  M0
                T3  N1  M0
Stage IVA  T4a  N0  M0  
               T4a  N1  M0
               T1  N2  M0
               T2  N2  M0
               T3  N2  M0
               T4a  N2  M0
Stage IVB  T4b  Any N  M0  
               Any T  N3  M0
Stage IVC  Any T  Any N  M1

**Clinical Stage Grouping by T and N Status**

<table>
<thead>
<tr>
<th>T1</th>
<th>T2</th>
<th>T3</th>
<th>T4a</th>
<th>T4b</th>
</tr>
</thead>
<tbody>
<tr>
<td>N0</td>
<td>I</td>
<td>II</td>
<td>III</td>
<td>IVa</td>
</tr>
<tr>
<td>N1</td>
<td>III</td>
<td>III</td>
<td>III</td>
<td>IVa</td>
</tr>
<tr>
<td>N2</td>
<td>IVa</td>
<td>IVa</td>
<td>IVa</td>
<td>IVa</td>
</tr>
<tr>
<td>N3</td>
<td>IVb</td>
<td>IVb</td>
<td>IVb</td>
<td>IVb</td>
</tr>
</tbody>
</table>
III. AJCC TUMOR STAGING—NASOPHARYNX AND THYROID

A. Nasopharynx

**Definition:** The nasopharynx includes the vault, the lateral walls, the posterior walls, and the superior surface of the soft palate.

**T1** Tumor is confined to the nasopharynx.

**T2** Tumor extends to soft tissues.

**T2a** Tumor extends to the oropharynx and/or nasal cavity, without parapharyngeal extension.

**T2b** Tumor extends into the parapharyngeal space.

**T3** Tumor involves bony structures and/or paranasal sinuses.

**T4** Tumor has intracranial extension and/or involves cranial nerves, infratemporal fossa, hypopharynx, orbit, or masticator space.

**Regional Lymph Nodes** (different from other head and neck sites)

**N0** There is no regional lymph node metastasis.

**N1** Unilateral metastasis in lymph node(s) is 6 cm or less in greatest dimension, above the supraclavicular fossa.

**N2** Bilateral metastasis in lymph nodes is 6 cm or less in greatest dimension, above the supraclavicular fossa.

**N3** Metastasis in lymph node(s) is greater than 6 cm and/or to the supraclavicular fossa.

**N3a** Tumor is greater than 6 cm in dimension.

**N3b** Tumor extends to the supraclavicular fossa.
**Stage Grouping** (unique to site)

<table>
<thead>
<tr>
<th>Stage</th>
<th>T (Primary Tumor)</th>
<th>N</th>
<th>M</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>Tis</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>I</td>
<td>T1</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>II A</td>
<td>T2a</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>II B</td>
<td>T1</td>
<td>N1</td>
<td>M0</td>
</tr>
<tr>
<td></td>
<td>T2</td>
<td>N1</td>
<td>M0</td>
</tr>
<tr>
<td></td>
<td>T2a</td>
<td>N1</td>
<td>M0</td>
</tr>
<tr>
<td></td>
<td>T2b</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td></td>
<td>T2b</td>
<td>N1</td>
<td>M0</td>
</tr>
<tr>
<td>III</td>
<td>T1</td>
<td>N2</td>
<td>M0</td>
</tr>
<tr>
<td></td>
<td>T2a</td>
<td>N2</td>
<td>M0</td>
</tr>
<tr>
<td></td>
<td>T2b</td>
<td>N2</td>
<td>M0</td>
</tr>
<tr>
<td></td>
<td>T3</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td></td>
<td>T3</td>
<td>N1</td>
<td>M0</td>
</tr>
<tr>
<td></td>
<td>T3</td>
<td>N2</td>
<td>M0</td>
</tr>
<tr>
<td>IVA</td>
<td>T4</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td></td>
<td>T4</td>
<td>N1</td>
<td>M0</td>
</tr>
<tr>
<td></td>
<td>T4</td>
<td>N2</td>
<td>M0</td>
</tr>
<tr>
<td>IVB</td>
<td>Any T</td>
<td>N3</td>
<td>M0</td>
</tr>
<tr>
<td>IVC</td>
<td>Any T</td>
<td>Any N</td>
<td>M1</td>
</tr>
</tbody>
</table>

**B. Thyroid**

*Definition:* The thyroid is composed of a right and left lobe, with an isthmus connecting the two lobes.

**Primary Tumor (T)**

TX  Primary tumor cannot be assessed.
T0  There is no evidence of primary tumor.
T1  Tumor is 2 cm or less in greatest dimension and is limited to the thyroid.
T2  Tumor is more than 2 cm but not more than 4 cm in greatest dimension, and is limited to the thyroid.
T3  Tumor is more than 4 cm in greatest dimension, and is limited to the thyroid or any tumor with minimal extrathyroid extension (e.g., extension to sternothyroid muscle or perithyroid soft tissues).

T4a  Tumor of any size extends beyond the thyroid capsule to invade subcutaneous soft tissues, larynx, trachea, esophagus, or recurrent laryngeal nerve.

T4b  Tumor invades prevertebral fascia or encases the carotid artery or mediastinal vessels.

**All anaplastic carcinomas are considered T4 tumors**

T4a  Intrathyroidal anaplastic carcinoma—surgically resectable.

T4b  Extrathyroidal anaplastic carcinoma—surgically unresectable.

**Regional Lymph Nodes (N)**

Regional lymph nodes are the central compartment, lateral cervical, and upper mediastinal lymph nodes.

NX  Regional lymph nodes cannot be assessed.

N0  There is no regional lymph node metastasis.

N1  There is regional lymph node metastasis.

N1a  There is metastasis to Level VI (pretracheal, paratracheal, and prelaryngeal/Delphian lymph nodes).

N1b  There is metastasis to unilateral, bilateral, or contralateral cervical or superior mediastinal lymph nodes.

**Distant Metastasis (M)**

MX  Distant metastasis cannot be assessed.

M0  There is no distant metastasis.

M1  There is distant metastasis.
Stage Grouping

Separate stage groupings are recommended for papillary or follicular, medullary, and anaplastic (undifferentiated) carcinoma.

Papillary or Follicular
(Younger than 45 years)
Stage I Any T Any N M0
Stage II Any T Any N M1

Papillary or Follicular
(45 years and older)
Stage I T1 N0 M0
Stage II T2 N0 M0
Stage III T3 N0 M0
T1 N1a M0
T2 N1a M0
T3 N1a M0
Stage IVA T4a N0 M0
T4a N1a M0
T1 N1b M0
T2 N1b M0
T3 N1b M0
T4a N1b M0
Stage IVB T4b Any N M0
Any T N3 M0
Stage IVC Any T Any N M1

Medullary Carcinoma
Stage I T1 N0 M0
Stage II T2 N0 M0
Stage III T3 N0 M0
T1 N1a M0
T2 N1a M0
T3 N1a M0
<table>
<thead>
<tr>
<th>Stage</th>
<th>T</th>
<th>N</th>
<th>M</th>
</tr>
</thead>
<tbody>
<tr>
<td>IVA</td>
<td>T4a</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td></td>
<td>T4a</td>
<td>N1a</td>
<td>M0</td>
</tr>
<tr>
<td></td>
<td>T1</td>
<td>N1b</td>
<td>M0</td>
</tr>
<tr>
<td></td>
<td>T2</td>
<td>N1b</td>
<td>M0</td>
</tr>
<tr>
<td></td>
<td>T3</td>
<td>N1b</td>
<td>M0</td>
</tr>
<tr>
<td></td>
<td>T4a</td>
<td>N1b</td>
<td>M0</td>
</tr>
<tr>
<td>IVB</td>
<td>T4b</td>
<td>Any</td>
<td>N</td>
</tr>
<tr>
<td></td>
<td>Any</td>
<td>T</td>
<td>N3</td>
</tr>
<tr>
<td>IVC</td>
<td>Any</td>
<td>T</td>
<td>Any</td>
</tr>
</tbody>
</table>

**Anaplastic Carcinoma**

*(All anaplastic carcinomas are considered Stage IV)*

<table>
<thead>
<tr>
<th>Stage</th>
<th>T</th>
<th>N</th>
<th>M</th>
</tr>
</thead>
<tbody>
<tr>
<td>IVA</td>
<td>T4a</td>
<td>Any</td>
<td>N</td>
</tr>
<tr>
<td>IVB</td>
<td>T4b</td>
<td>Any</td>
<td>N</td>
</tr>
<tr>
<td>IVC</td>
<td>Any</td>
<td>T</td>
<td>Any</td>
</tr>
</tbody>
</table>